Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824467 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
A Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
- 20
- Study locations
NCT06824467: Recruiting Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Merck Sharp & Dohme.
NCT06824467 is a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 770 participants, roughly in line with the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target. The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06824467, a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- BIOLOGICAL Bevacizumab
- DRUG H1 receptor antagonist
- DRUG H2 receptor antagonist
- DRUG Acetaminophen (or equivalent)
Study Locations (20)
Florida
- Mount Sinai Cancer Center ( Site 0078) - Miami Beach
- Sarasota Memorial Hospital ( Site 0075) - Sarasota
- Florida Cancer Specialists East ( Site 7000) - West Palm Beach
New York
- NYU Langone Hospital - Long Island ( Site 0015) - Mineola
- Laura and Isaac Perlmutter Cancer Center ( Site 0076) - New York
Alabama
- University of Alabama at Birmingham ( Site 0006) - Birmingham
Connecticut
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) - New Haven
Georgia
- Augusta University - Georgia Cancer Center ( Site 0066) - Augusta
Indiana
- Parkview Research Center at Parkview Regional Medical Center ( Site 0003) - Fort Wayne
Louisiana
- Women's Cancer Care ( Site 0067) - Covington
Maine
- Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008) - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2032-11-09 |
| Phase | Phase 3 |
What NCT06824467 shows while recruiting
NCT06824467 is an interventional study that assigns participants to a tested intervention. The registered 770 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT06824467 names 20 study sites across 17 states, led by Florida, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT06824467 about?
NCT06824467 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)". The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
What is the current status of trial NCT06824467?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2025-04-09. Estimated completion is 2032-11-09.
What conditions does trial NCT06824467 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.
What interventions are being tested in trial NCT06824467?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Bevacizumab (BIOLOGICAL), H1 receptor antagonist (DRUG), H2 receptor antagonist (DRUG), Acetaminophen (or equivalent) (DRUG).
Who is sponsoring clinical trial NCT06824467?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824467 being conducted?
This trial has 20 study locations across Alabama, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06824467's enrollment target sits among peer trials
770 32nd of 322 higher than 291 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05977348 · 770 participants · NA
Increasing Food Literacy in Preschoolers to Reduce Obesity Risk
- NCT06376994 · 770 participants · Phase 3
Multi-Center Clean Air Randomized Controlled Trial in COPD
- NCT06907173 · 770 participants · Phase 3
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
- NCT07209254 · 770 participants · NA
Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI